Novel preparation method of lenalidomide

A technology of lenalidomide and glutamine, which is applied in the field of pharmaceutical chemical synthesis, can solve the problems of low total yield, long steps, and difficulty in industrialization, and achieve the effects of low production cost, short reaction steps, and no three wastes

Active Publication Date: 2013-07-10
HANGZHOU BIO SINCERITY PHARMA TECH CO LTD
View PDF4 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] In view of this, in order to solve the shortcomings of the existing lenalidomide preparation technology, such as long steps, low total yield, and difficulty in realizing industrialization, the pr

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel preparation method of lenalidomide
  • Novel preparation method of lenalidomide
  • Novel preparation method of lenalidomide

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0026] Example 1:

[0027] (1) Preparation of 3-N-Boc-aminopiperidine-2,6-dione

[0028] 41.6 g of N-Boc-L-glutamine was dissolved in 200 mL of 2-methyltetrahydrofuran, and 35.1 g of DCC was added under ice bath at 0°C, and reacted at room temperature for 10 hours. Recover the solvent, extract three times with ethyl acetate, combine the organic layers, and use saturated NaHCO 3 , Wash with saturated brine, dry with anhydrous sodium sulfate, recover the solvent to obtain 28.9 g of white solid, the yield is 75%. 1 H NMR (500 MHz, CDCl 3 ) δ: 8.17 (brs, 1H), 5.36 (brs, 1H), 4.33-4.30 (m, 1H), 2.82-2.77 (m, 1H), 2.72-2.64 (m, 1H), 2.54-2.51 (m, 1H), 1.91-1.82 (m, 1H), 1.46 (s, 9H)

Example Embodiment

[0029] Example 2:

[0030] 41.6 g of N-Boc-L-glutamine was dissolved in 200 mL of 2-methyltetrahydrofuran, 35.1 g of DCC was added under an ice bath at 0°C, and reacted at room temperature at 40°C for 10 hours. Recover the solvent, extract three times with ethyl acetate, combine the organic layers, and use saturated NaHCO 3 , Wash with saturated brine, dry with anhydrous sodium sulfate, recover the solvent to obtain a white solid, the yield is 78%.

Example Embodiment

[0031] Example 3:

[0032] (2) Preparation of 3-aminopiperidine-2,6-dione hydrochloride

[0033] 10 g of 3-N-Boc-aminopiperidine-2,6-dione was dissolved in 30 mL of HCl saturated ethyl acetate, stirred at room temperature for 8 hours, and filtered with suction to obtain 6.47 g of white solid with a yield of 90%. 1 H NMR (500 MHz, DMSO-d 6 ): 11.26 (s, 1H), 8.74 (s, 3H), 4.21 (dd, J 1 =13.0 Hz, J 2 = 5.0 Hz, 1H), 2.76-2.68 (m, 1H), 2.61-2.51 (m, 1H), 2.25-2.23 (m, 1H), 2.09-2.00 (m, 1H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a method for preparing lenalidomide (3-(7-amino-3-oxo-1H-isoindazole-2-yl) piperidine-2,6-diketone). The method comprises the steps of: intramolecular cyclization, deprotection, phase-transfer catalytic reaction, catalytic hydrogenation, alkalization and the like. The technology is novel in path, short in step, high in reaction yield, and low in production cost, and has large implementation value and social and economic benefits.

Description

technical field [0001] The invention belongs to the field of pharmaceutical chemical synthesis, in particular to a new preparation method of lenalidomide. Background technique [0002] Lenalidomide (3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione) is a new type of immune The modulator, which was approved by the US FDA in January 2006, with the trade name Revlimid, is mainly used clinically for the treatment of myelodysplastic syndrome (MDS) subtypes and multiple myeloma. [0003] Multiple myeloma (multiple myeloma, MM) is a refractory malignant B-cell disease, the patients' bone marrow malignant cells continue to proliferate so that normal cells cannot function. Myelodysplastic syndrome (MDS) is a clonal hematopoietic neoplasm that occurs when blood cells in the bone marrow, which fills with immature cells, are unable to perform their necessary functions , inhibiting the development of normal cells. [0004] Chemotherapy for MM and MDS began in the 1960s. In the f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D401/04
Inventor 曾智丽盛荣竺彬赵丽英王美红
Owner HANGZHOU BIO SINCERITY PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap